USPSTF: Evidence Lacking for Screening for Speech and Language Delays

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 23, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, Jan. 23, 2024 -- The U.S. Preventive Services Task Force (USPSTF) concludes that the evidence is currently inadequate for recommending primary care screening for speech and language delay and disorders among asymptomatic children aged 5 years and youngert. These findings form the basis of a final recommendation statement published in the Jan. 23/30 issue of the Journal of the American Medical Association.

Cynthia Feltner, M.D., M.P.H., from RTI International-University of North Carolina at Chapel Hill Evidence-based Practice Center, and colleagues reviewed the evidence on screening for speech and language delay or disorders in children aged 5 years or younger to inform the USPSTF. Thirty-eight studies from 41 articles were included, with 9,006 participants. The researchers found that none of the studies assessed the direct benefits of screening versus no screening. Consistently high sensitivity and specificity were found in three studies assessing parent-reported tools for expressive language skills. There was wide variation noted in the accuracy of other screening tools. Benefit was found for different measures of expressive language skills in two randomized controlled trials evaluating relatively intensive parental group training interventions; no difference was seen for any outcomes in one trial assessing a less intensive intervention.

Based on these findings, the USPSTF concludes that the current evidence is inadequate for assessing the balance of benefits and harms of screening for speech and language delay and disorders among children without signs or symptoms or parent/caregiver-reported concerns (I statement).

"In the absence of evidence, health care professionals should use their judgment when deciding whether or not to screen children who are not showing signs of speech and language delay and disorders," USPSTF member Li LI, M.D., Ph.D., M.P.H., from the University of Virginia School of Medicine in Charlottesville, said in a statement.

Evidence Report

Final Recommendation Statement

Editorial

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords